Investment Analysts’ Recent Ratings Updates for Allogene Therapeutics (ALLO)

Allogene Therapeutics (NASDAQ: ALLO) has recently received a number of price target changes and ratings updates: 11/14/2024 – Allogene Therapeutics had its price target lowered by analysts at Piper Sandler from $11.00 to $9.00. They now have an “overweight” rating on the stock. 11/14/2024 – Allogene Therapeutics had its “outperform” rating reaffirmed by analysts at […]

Leave a Reply

Your email address will not be published.

Previous post Cisco Reports 4th Consecutive Revenue Decline, Looks to AI for Growth Revival
Next post Meeder Advisory Services Inc. Purchases 42 Shares of S&P Global Inc. (NYSE:SPGI)